Perfusion

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matheis, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matheis, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Perfusion, Vol. 18, No. 4, 245-251 (2003)
DOI: 10.1191/0267659103pf684oa

New technologies for respiratory assist

Georg Matheis

NovaLung, Hechingen, Germany, georg.matheis{at}novalung.com

‘The artificial lung especially has lingered behind progress with artificial hearts and ventricular assist devices, not because the need for lungs has not been recognized, but because we have not had a full understanding of the engineering problems and the unique material requirements until recent years.’1

Brack Hattler, MD PhD

The development from the first clinical use of haemo-dialysis over five decades ago to widespread chronic treatment took more than two decades. The histories of other artificial organ technologies, such as artificial hearts, follow similar long development paths. For five decades, due to a lack of technology, artificial lungs have been limited to use with a heart-lung machine for cardiopulmonary bypass (CPB) or extracorporeal membrane oxygenation (ECMO). The advent of pumpless biocompatible artificial lungs will open new treatment options for patients with acute or chronic lung failure.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 PerfusionHome page
A. Philipp, T. Muller, T. Bein, M. Foltan, F.-X. Schmid, D. Birnbaum, and C. Schmid
Inhibition of thrombocyte aggregation during extracorporeal lung assist: a case report
Perfusion, July 1, 2007; 22(4): 293 - 297.
[Abstract] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. Iglesias, P. Jungebluth, O. Sibila, I. Aldabo, M. P. Matute, C. Petit, A. Torres, and P. Macchiarini
Experimental safety and efficacy evaluation of an extracorporeal pumpless artificial lung in providing respiratory support through the axillary vessels
J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 339 - 345.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
Bridge to lung transplantation with the novel pumpless interventional lung assist device NovaLung.
J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 719 - 723.